CMS’ Likely Reversal Of Threat To Part D Protected Classes Doesn’t Mean Other Reforms Aren’t Coming

Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.

Patient Concerns Will Probably Thwart Efforts To Restrict Protected Classes Again

The Centers for Medicare and Medicaid Services is likely to consent to pleas from patient groups and others to reverse a Trump Administration policy that would allow Medicare Part D plans participating in a payment demonstration project to cover only one drug in the protected classes beginning in 2022, essentially waiving the “substantially all” coverage requirement for the purposes of the experiment.

The change, made on the final day of the Trump Administration, was meant to attract more participation in the Medicare...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Medicare

More from Government Payers